Overview

Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

Status:
Recruiting
Trial end date:
2029-07-21
Target enrollment:
Participant gender:
Summary
The purpose of this Phase 3 study is to evaluate the efficacy and safety of iptacopan upon switching from anti-C5 antibody to iptacopan treatment in study participants with aHUS.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals